Saturday 17 October 2026 Export VOR’s income statement to Excel — free account

Vor Biopharma Inc.

VOR Healthcare Biotechnology

18.03 1.31 −6.77%

Follow VOR

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 49.42

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	5	—	—	1	—	—	—

Insider Ownership 52.03%

Capital & Financial Ratios $m

Market Cap 1,140.00

Revenue —

Net Income 0.00

Free Cash Flow (94.61)

Net Debt (123.50)

Current Ratio 10.69

Debt/Equity 0.21

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 6.97

Past 5Y EPS Growth —

This Y EPS Growth 89.70%

Next Y EPS Growth 49.75%

Next Y revenue growth —

Next 5Y EPS Growth 61.59%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 22.17%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2020	2021	2022	Q'23
Cash	49	207	230	160
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	1	7	7	4
	49	214	237	164

	2020	2021	2022	Q'23
Payables	2	2	2	1
ST’ Debt	1	2	3	4
Other	7	7	8	10
	10	10	13	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	—	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	—	220.11%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(24)	(24)	(28)	—	—
’22	(22)	(17)	(19)	(18)	(85)
’21	(18)	(15)	(17)	(17)	(69)
’20	(6)	(9)	(9)	(13)	(36)
’19	—	—	—	(6)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(24)	(24)	(28)	—	—
’22	(22)	(17)	(19)	(18)	(85)
’21	(18)	(15)	(17)	(17)	(69)
’20	(6)	(9)	(9)	(13)	(36)
’19	—	—	—	(6)	(10)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(5.11)	(1.16)	—	—	—
’25	(5.20)	(251.20)	(121.63)	—	(70.50)
’24	(9.00)	(8.20)	(8.00)	(8.80)	(34.00)
’23	(8.60)	(9.00)	(9.80)	(7.80)	(35.00)
’22	(12.20)	(11.60)	(12.60)	(10.60)	(46.60)
’21	(13.40)	(10.00)	(10.00)	(9.80)	(42.00)
’20	(0.23)	(0.24)	(0.38)	(0.48)	(4.61k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	209.60	69.60	32.40	12.60	2.62	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	1,272.40	254.60	142.80	62.80	65.80
People
People	Employees	—	—	—	—	—	—	—	—	—	—
	Revenue/emp, $m	—	—	—	—	—	—	—	—	—	—
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	(4)	(11)	(43)	(69)	(92)	—	—	—
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	Net income	—	0	(4)	(11)	0	0	0	0	0	0
	Depreciation	—	—	0	0	1	4	9	—	—	—
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(0.11)	(0.34)	(4,611.40)	(42.00)	(46.60)	(35.00)	(34.00)	(70.50)
	Cash flow	—	—	(0.07)	(0.27)	(3,860.85)	(42.15)	(43.08)	0.00	0.00	0.00
	Capex	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	(0.07)	(0.27)	(3,860.85)	(42.15)	(43.08)	0.00	0.00	0.00
	Book value	—	—	(0.18)	0.21	5,135.21	131.83	126.81	0.00	0.00	0.00
	Shares, m	—	—	37	37	0	2	2	3	3	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(3)	(10)	(36)	(69)	(85)	—	—	—
	Capex	—	—	—	(1)	(4)	(4)	(8)	—	—	—
	Free cash flow	—	—	(3)	(10)	(36)	(69)	(85)	—	—	—
Balance, $m
Balance, $m	Working capital	—	—	(7)	5	39	204	224	—	—	—
	Total debt	—	—	4	—	18	18	39	—	—	—
	Net debt	—	—	4	(6)	(30)	(189)	(191)	—	—	—
	Shareholders’ equity	—	—	(7)	8	48	216	251	—	—	—
Returns, %
Returns, %	ROA	—	—	(824.63)	(232.84)	(882.09)	0.00	0.00	0.00	0.00	0.00
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	—	—	—
	ROE	—	—	34.32	104.24	113.31	(87.66)	(39.45)	0.00	0.00	0.00

Negative figures in brackets.

All 10 years →

Fundamentals updated 5 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%	Compare
SNDX Syndax Pharmaceuticals, Inc.	$1.2B	— (loss-making)	— (loss-making)	+91.76% (above 0%: growing)	n/m	+65.47% (above 0%: growing)	95.59%	(54.95%)	Compare
LBRX LB Pharmaceuticals Inc	$1.2B	— (loss-making)	—	—	n/m	−579.03% (below 0%: shrinking)	—	0.00%	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—
NBTX Nanobiotix S.A. - Sponsored ADR	$1.1B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%	Compare
REPL Replimune Group, Inc.	$1.1B	— (loss-making)	—	—	n/m	+5.04% (above 0%: growing)	0.00%	0.00%	Compare
IMTX Immatics N.V.	$1.1B	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)	Compare
Median of peers	$1.2B	—	—	+91.76%	—	−58.68%	0.00%	0.00%

All 614 Biotechnology stocks →

Vor Biopharma Inc. (VOR) key facts

Vor Biopharma Inc. (VOR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VOR traded at $18.03, a market capitalization of $1.1 billion.
Return on equity was 0.00% and debt-to-equity 0.21.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 5, 2026.